Merck, Inc.
🇺🇸United States
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
Phase 2
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevnar 13™Biological: V114
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 253
- Registration Number
- NCT02573181
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Phase 3
Completed
- Conditions
- Esophageal CarcinomaEsophagogastric Junction Carcinoma
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 628
- Registration Number
- NCT02564263
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02564211
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Phase 3
Completed
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT02563002
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
- Interventions
- Drug: [18F]MK-6240, ~185 MBqDrug: [18F]MK-6240, ~160 MBq
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT02562989
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Phase 2
Completed
- Conditions
- Esophageal CarcinomaEsophagogastric Junction Carcinoma
- Interventions
- Biological: pembrolizumab
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 121
- Registration Number
- NCT02559687
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Phase 3
Completed
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 622
- Registration Number
- NCT02555657
Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)
Phase 1
Terminated
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: MK-1248Biological: pembrolizumab
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT02553499
Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)
Phase 1
Completed
- Conditions
- Human Immunodeficiency Virus-1 (HIV-1)
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02549040
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02549014
© Copyright 2025. All Rights Reserved by MedPath